BioProspect cops Euro setback
Friday, 01 July, 2005
Brisbane natural pesticide developer BioProspect (ASX:BPO) faced a setback this week, after its potential European licensee, Germany's W Neudorff, declined to pursue development of BioProspect's eucalyptus-derived biocide for carpet beetles and clothes moths.
Neudorff cited concerns about the estimated cost of manufacturing and registering a formulated Qcide product for Germany and Europe.
Only three months ago, BioProspect received a similar knockback from another potential partner, Sumitomo Australia. At the time, Bioprospect said the Neudorff trials were "progressing very well".
In the wake of thefailed deal, the company said it was continuing with other confidential evaluation agreements in Australia and the US for the consumer goods and animal markets.
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
High folic acid in pregnancy could cause early bleeding
Women taking at least 800 micrograms of folic acid daily were more likely to report spotting and...
